TL;DR
The regulatory landscape is shifting toward collaborative pathways under new leadership, marked by the revival of previously stalled clinical programs and the landmark acceptance of the FDA's first-ever computational tool for predicting drug-induced liver injury. Meanwhile, a critical biosecurity crisis has emerged in the U.S. Southwest with the first domestic outbreak of the destructive New World screwworm in sixty years. Concurrently, pediatric immunology has reached a major milestone with the first targeted IL-23 inhibitor approved for young children.
A Domestic Biosecurity Crisis Collides with Infrastructure Delays
A forgotten ecological threat is rapidly gaining a foothold in the American Southwest as infrastructure delays hobble the eradication response.
"The U.S. Department of Agriculture has confirmed 31 New World screwworm infestations, including 30 in Texas and one in New Mexico, as federal and state officials continue working to contain the flesh-eating parasite..." — new-world-screwworm-us-outbreak
+1
The re-emergence of this flesh-eating parasite for the first time since it was declared eradicated in 1966 represents an immediate threat to livestock, wildlife, and domestic pets. The inability to deploy sterile flies at the necessary scale to collapse the wild population highlights a critical gap between localized agricultural crises and federal infrastructure execution.
What to watch: Watch whether the alternative facility in Chiapas, Mexico, can successfully scale up production beyond its current release rate of 50 million sterile flies per week to meet the estimated 500 million needed to halt the outbreak new-world-screwworm-us-outbreak.
The FDA's Dual Path: Reclaiming Advisory Committees and Embracing Silicon Safety
The FDA is simultaneously lowering barriers to entry for advanced clinical pipelines and pioneering computational safety pathways to accelerate drug development.
"With this action, FDA is supporting innovative ways to optimize the development and evaluation of potential new therapies... The AI-Driven Digital Liver Model shows promise in assessing the risk of hepatotoxicity during preclinical phases of drug development." — fda-istand-first-in-silico-drug-development-tool
"A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership... Wall Street analysts believe, by and large, that the agency is on the verge of returning to a more industry-friendly approach..." — fda-regulatory-pivot-advisory-committees-capricor-replimune
Under acting Commissioner Kyle Diamantas, the agency is pairing a highly collaborative stance on previously rejected clinical therapies with a forward-looking embrace of computational tools like DILIPredictor to bypass traditional, slow-moving safety paradigms fda-regulatory-pivot-advisory-committees-capricor-replimune, fda-istand-first-in-silico-drug-development-tool
. This dual strategy significantly de-risks early-stage development while smoothing the path for late-stage regulatory resubmissions.
What to watch: Watch for the outcome of Capricor's upcoming advisory committee meeting scheduled for July 29, 2026, which will serve as a bellwether for how the agency handles previously rejected applications fda-regulatory-pivot-advisory-committees-capricor-replimune.
Blockbuster Immunology Secures an Early-Intervention Foothold
Targeted immunology therapies are successfully moving down the age bracket, establishing new standards of care for pediatric chronic diseases.
"We are proud that SKYRIZI is now the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis." — fda-approval-skyrizi-pediatric-psoriasis-arthritis
This approval brings highly targeted, weight-based biologic options to younger patients who previously lacked access to advanced IL-23 inhibition fda-approval-skyrizi-pediatric-psoriasis-arthritis. By introducing a new 55 mg syringe, AbbVie is effectively carving out a dominant, early-intervention niche in the pediatric immunology market fda-approval-skyrizi-pediatric-psoriasis-arthritis.
What to watch: Watch for how rapidly pediatric dermatologists adopt this weight-based dosing regimen for children under 40 kg.
What surprised us
- A critical biosecurity defense is stalled by a multi-year construction delay. Despite Congress allocating $610 million, the USDA's planned sterile fly facility in Edinburg, Texas, will not be operational until late 2027, leaving the U.S. dangerously dependent on Mexican facilities during an active, flesh-eating parasite outbreak new-world-screwworm-us-outbreak
- The FDA accepted its first-ever computational tool to predict liver injury. By admitting DILIPredictor into the ISTAND program, the FDA has officially opened a three-step pathway to qualify in silico tools that could eventually replace animal testing for hepatotoxicity fda-istand-first-in-silico-drug-development-tool
.
- Sobi's gout therapy was rejected purely on third-party manufacturing grounds. The FDA's Complete Response Letter for NASP contained no concerns regarding clinical safety or efficacy, pointing instead to a "third-party manufacturing indictment" that stalls an otherwise clean drug candidate fda-regulatory-pivot-advisory-committees-capricor-replimune